

# CLINICAL RESEARCH

## NEWSLETTER

JANUARY 2026  
VOLUME 1 | ISSUE 10

### • CORE Fundamentals Training



The CORE Research Fundamentals Training Program equips clinical research professionals with the essential knowledge and tools to conduct high-quality cancer clinical trials across the Georgia NCORP



FEBRUARY 2-3, 2026  
AT 9:00AM - 4:00 PM



#### What You'll Learn:

- Cancer Basics 101
- Clinical Trials 101
- Research Roles & Responsibilities
- Informed Consent Process &
- Documentation
- Regulatory Compliance
- Eligibility Screening &
- Enrollment
- Safety Reporting (AEs, SAEs, UPS)
- Protocol Interpretation &
- Compliance
- Good Documentation Practices

Upon completion of this class, you will receive CEU Credits!

**CONTACT US**



404-523-8735 ext. 4 [www.georgiacancerinfo.org](http://www.georgiacancerinfo.org)

### Inside this issue

TOPIC	PAGE
CORE Fundamentals/ECOG Audit	1
Enrolling CCDR Trials	2
Recently Opened GA NCORP Trials	3
Pending Activation/GCTF	4
Test Your Knowledge Quiz/GA NCORP SP	5
Upcoming Meetings & Kudos/CCDR Accrual	6

### ECOG-ACRIN Audit

Our most recent ECOG-ACRIN audit took place on May 22, 2023, and we remain on a three-year audit cycle. Based on this schedule, we expect formal notification of our next audit in mid-March 2026, as ECOG-ACRIN typically provides approximately six weeks' notice.

To support audit readiness, we encourage all sites to begin early preparation. In the coming weeks, the Georgia CORE team will reach out to schedule monitoring visits focused on reviewing documentation completeness, identifying potential gaps, and strengthening overall compliance. If there are specific charts you would like prioritized for review, please let us know, otherwise charts will be selected at random.

We will also distribute any outstanding action items from previously reviewed charts so they can be addressed promptly or discussed with our team if assistance is needed.

### STOP-VTE Survey

Wake Forest new Cancer Care CCDR Study, WF-2502CD, Surgical Thromboprophylaxis Practices in Oncology Patients within the NCORP Network (STOP-VTE). This study has 3 parts: 1) The STOP-VTE Survey, 2) Surgeon and Advanced Practice Provider (APP) Qualitative Interviews and 3) EHR Data Extraction.

A site needs to obtain IRB approval prior to submitting the interest survey to participate in the study as a whole.

### Contact Info

GA NCORP CCDR Program  
Stephanie Reyes, RN, MSN, OCN: [smiths1@sjchs.org](mailto:smiths1@sjchs.org)  
(while Alaina Newsome is OOO)

# CLINICAL RESEARCH

## NEWSLETTER

JANUARY 2026  
VOLUME 1 | ISSUE 10

### ALL OPEN AND ENROLLING CANCER CARE DELIVERY RESEARCH (CCDR) TRIALS<sup>1</sup>

Research Base	Title	CTSU Activation Date
Alliance	A232301CD: AYA Access Study: An Enhanced eHealth and Chat-Bot Enabled Delivery Model for Clinical Genetic Services in Community AYA Cancer Patients	9/26/2025
	A232402CD: PAGODA: Randomized Trial of a Proactive Graduated Dose Modification Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays	1/06/2026
ECOG-ACRIN	EAQ221CD: Mobile Health for Adherence in Breast Cancer Patients (CONCURxP) <i>Deemed high priority by the Executive Committee.</i>	10/31/2023
	EAQ222CD: Cost Communication and Financial Navigation in Cancer Patients (COSTCOM) <i>Sites must receive approval prior to initiating any study start-up activities.</i>	2/29/2024
SWOG	S2417CD: A Pragmatic Randomized Controlled Trial To Evaluate The Effectiveness of an Intervention called Current Together After Cancer (CTAC) to Promote Guideline-Concordant Colorectal Cancer Surveillance	8/4/2025
Wake Forest	WF-1805CD: Implementation and Effectiveness Trial of HN-STAR <i>Participant enrollment closed as of 2/13/2025, but practice (non-patient) enrollment is now ongoing.</i>	8/10/2020
	WF-2301CD: Multi-site Community Oncology Planning for the CONNECT Intervention Targeting Lung Cancer Caregivers <sup>2</sup> <i>Closed to accepting new sites. Contact Jess Sheedy (jsheedy@wakehealth.edu) to get on the waitlist.</i>	7/2/2024
	WF-2303CD: Understanding and Enhancing Health-Related Social Needs (HRSN) Screening Among Community Oncology Practice <i>Closed to accepting new sites. Contact Jess Sheedy (jsheedy@wakehealth.edu) to get on the waitlist.</i>	7/23/2024
	WF-2502CD: Surgical Thromboprophylaxis Practices in Oncology Patients within the NCORP Network (STOP-VTE)	12/02/2025

# CLINICAL RESEARCH

## NEWSLETTER

JANUARY 2026  
VOLUME 1 | ISSUE 10

### Recently Activated and Recommended Trials<sup>1</sup>

Research Base	Title	CTSU Activation Date
SWOG	LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)	10/22/2025
	S2433: Randomized Phase III Study of Second-Line Chemotherapy with or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma	12/26/2025
ECOG	EA1241: Extended Clinical Follow up and Biospecimen Collection for Patients Enrolled in TAILORx and RxPONDER: A Companion Protocol	12/4/2025
NRG	NRG-GY035: A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab Versus Carboplatin, Paclitaxel, Bevacizumab Versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer	1/12/2026
	NRG-HN015: A Phase II Randomized Trial of Neoadjuvant Chemotherapy or Chemo-Immunotherapy in Patients with Recurrent/Persistent PD-L1 Enriched Squamous Cell Carcinoma of the Head and Neck Undergoing Salvage Surgery (NEOPOLIS)	1/12/2026
Alliance	A232402CD: PAGODA: Randomized Trial of a Proactive Graduated Dose Modification Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays	1/06/2026
	A032304: Radioligand Efficacy Comparison by Initial PSA-Response Outcome in Metastatic CRPC with Lutetium 177Lu PSMA RLT (RECIPROCAL)	12/23/2025
Wake Forest	WF-2501CD: Practical Delivery of Geriatric Assessment in Community Oncology Settings (PGA)	12/02/2025
	WF-2502CD: Surgical Thromboprophylaxis Practices in Oncology Patients within the NCORP Network (STOP-VTE)	12/02/2025

# CLINICAL RESEARCH

## NEWSLETTER

JANUARY 2026  
VOLUME 1 | ISSUE 10

### CANCER CARE DELIVERY RESEARCH (CCDR) TRIALS PENDING ACTIVATION

Research Base	Title	Description
ECOG-ACRIN	EAQ241CD: FinFit: Addressing Financial Hardship in AYA Cancer Survivors	<ul style="list-style-type: none"><li>Recruiting 408 AYAs</li><li>Protocol being prepared at ECOG-ACRIN</li><li>Expected start: Winter 2025</li></ul>

### Did You Know?

Georgia Cancer Trial Finders (GCTF) is a free, statewide Georgia CORE resource that helps identify oncology clinical trials located in Georgia. If you do not have a suitable trial available within your current research portfolio for your patient, GCTF can assist in determining whether other trials in Georgia may be available. By maintaining a network of research coordinators across the state, the GCTF Clinical Trials Navigator can connect you directly—via email—to sites actively conducting research, helping to save time and reduce back-and-forth communication.

In addition to NCORP trials, we encourage you to share your broader trial portfolio so we can refer patients who may be a fit for your studies. Trial portfolios and inquiries may be sent to [navigator@georgiacore.org](mailto:navigator@georgiacore.org). Learn more at [www.GeorgiaCancerInfo.org/TrialFinders](http://www.GeorgiaCancerInfo.org/TrialFinders) and submit a patient referral here.

# CLINICAL RESEARCH

## NEWSLETTER

JANUARY 2026  
VOLUME 1 | ISSUE 10

### TEST OF YOUR KNOWLEDGE QUIZ!

The first person to answer correctly will receive **Georgia NCORP swag** and a shout-out in the next issue!  
Send your responses to [kdixon@georgiacore.org](mailto:kdixon@georgiacore.org).

1. **The primary goal of a Phase I oncology clinical trial is to:**
  - A. Evaluate overall survival
  - B. Compare the investigational drug to standard of care
  - C. Determine safety, tolerability, and recommended dose
  - D. Assess quality of life outcomes
2. **The Common Terminology Criteria for Adverse Events, commonly abbreviated as \_\_\_\_\_, is used to standardize the classification and grading of adverse events in oncology trials.**
3. **Which biomarker is most commonly associated with targeted therapy selection in non-small cell lung cancer (NSCLC)?**
  - A. HER2
  - B. BRAF
  - C. EGFR
  - D. BRCA1

### Georgia CORE SharePoint Site Relaunch

We are excited to announce the relaunch of the Georgia CORE SharePoint site, your centralized hub for program resources and updates. This site is designed to streamline communication and provide easy access to key materials, including Georgia CORE templates, the GA NCORP calendar for site visits, audits, and conferences, the accrual dashboard, and other important program announcements.

We encourage all sites to bookmark the portal and begin using it as your primary reference for program tools and information. This is not meant to be another place to check, it is meant to replace the scattered emails and attachments that slow everyone down. Start using it this week so it actually becomes part of your workflow.

# CLINICAL RESEARCH

## NEWSLETTER

JANUARY 2026  
VOLUME 1 | ISSUE 10

### Upcoming Research base Meetings\*

Research Base	Date	Location
NRG	January 22-24, 2026	San Francisco, CA
SWOG	April 30-May 2, 2026	San Francisco, CA
	October 8-10, 2026	Chicago, IL
ECOG	May 5-7, 2026	Baltimore, MD
	October 20 - 22, 2026	Philadelphia, PA
URCC	September 25-27, 2026	Niagara Falls, NY
Wake Forest	October 12-14, 2026	Myrtle Beach, SC
<b>UPCOMING ROUTINE AUDITS<sup>1</sup></b>		
ECOG	TBD FOR 2026	Exact dates and method (onsite vs virtual) are pending.
NRG	TBD	
SWOG	TBD for 2027	
URCC	TBD for 2027	
Wake Forest	TBD for 2027	

\*Please contact Shantoria Brown ([sbrown@georgiacore.org](mailto:sbrown@georgiacore.org)) to discuss travel funds and audit preparation.

### GA NCORP Program Kudos

Sites GA024, GA031 and GA106, for their enrollment efforts for DCP-001 this past month.

Way to go!

### GA NCORP CCDR Accruals to date for Year 12

Study	Accrual to date
EAQ221CD	5
<b>Totals</b>	<b>5</b>